2Alm P,Alumets J,Hkanson R,et al.Peptidergic (vasoactive intestinal peptide) nerves in the genito-urinary tract[J].Neuroscience,1977,2(5):751-754.
3Moody TW,Chan D,Fahrenkrug J,et al.Neuropeptides as autocrine growth factors in cancer cells[J].Curr Pharm Des,2003,9(6):495-509.
4Collado B,Carmena MJ,Clemente C,et al.Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model[J].Peptides,2007,28(9):1896-1901.
5Fernndez-Martinez AB,Bajo AM,Sanchez-Chapado M,et al.Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells[J].Prostate,2009,69(7):774-786.
6Fernndez-Martinez AB,Bajo AM,Isabel-arenas M,et al.Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1[J].Cancer Lett,2010,299(1):11-21.
7Mack D,Hacker GW,Hauser-Kronberger C,et al.Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma[J].Eur J Cancer,1997,33(2):317-318.
8Garbett EA,Reed MW,Brown NJ.Proteolysis in human breast and colorectal cancer[J].Br J Cancer,1999,81(2):287-293.
9Madigan MC,Kingsley EA,Cozzi PJ,et al.The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression[J].Cancer Immunol Immunother,2008,57(9):1367-1379.
10Komuro H, Kaneko S, Kaneko M, et al. Expression of angiogenic fac- tors and tumor progression in human neuroblastoma. J Cancer Res Clin Onco1,2001,127 :739-743.
